ES2146648T3 - Procedimiento de aislamiento de proteinas de la leche. - Google Patents

Procedimiento de aislamiento de proteinas de la leche.

Info

Publication number
ES2146648T3
ES2146648T3 ES94910120T ES94910120T ES2146648T3 ES 2146648 T3 ES2146648 T3 ES 2146648T3 ES 94910120 T ES94910120 T ES 94910120T ES 94910120 T ES94910120 T ES 94910120T ES 2146648 T3 ES2146648 T3 ES 2146648T3
Authority
ES
Spain
Prior art keywords
isolation
procedure
interest
milk proteins
solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910120T
Other languages
English (en)
Inventor
Julie S Denman
Edward S Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ES2146648T3 publication Critical patent/ES2146648T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C3/00—Preservation of milk or milk preparations
    • A23C3/08—Preservation of milk or milk preparations by addition of preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/832—Milk; colostrum

Abstract

SE DESCRIBEN METODOS PARA AISLAR LOS COMPONENTES DE INTERES DE UNA MUESTRA DE LECHE. EL METODO CONSISTE EN UN PASO EN DONDE LA SOLUBILIDAD DE AL MENOS UNA PORCION DE LA PROTEINA DE LA LECHE ENTERA SE ESTABILIZA DE TAL MODO QUE SE PUEDA AISLAR EL COMPONENTE DE INTERES SIN QUE TENGA LUGAR UNA PERDIDA SIGNIFICATIVA DE LA RIQUEZA DEL PRODUCTO. TAMBIEN SE DESCRIBEN KITS PARA ESTABILIZAR LA SOLUBILIDAD DE AL MENOS UNA PORCION DE LA PROTEINA DE LA LECHE ENTERA DE LA MUESTRA DE LECHE QUE CONTIENE EL COMPONENTE DE INTERES.
ES94910120T 1993-03-09 1994-02-17 Procedimiento de aislamiento de proteinas de la leche. Expired - Lifetime ES2146648T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2839593A 1993-03-09 1993-03-09

Publications (1)

Publication Number Publication Date
ES2146648T3 true ES2146648T3 (es) 2000-08-16

Family

ID=21843236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910120T Expired - Lifetime ES2146648T3 (es) 1993-03-09 1994-02-17 Procedimiento de aislamiento de proteinas de la leche.

Country Status (11)

Country Link
US (1) US5756687A (es)
EP (1) EP0804070B1 (es)
JP (1) JP3801196B2 (es)
AT (1) ATE193301T1 (es)
AU (1) AU693436B2 (es)
DE (1) DE69424687T2 (es)
DK (1) DK0804070T3 (es)
ES (1) ES2146648T3 (es)
GR (1) GR3033500T3 (es)
PT (1) PT804070E (es)
WO (1) WO1994019935A1 (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP0933029A1 (en) * 1998-02-03 1999-08-04 Xyrofin Oy Skimmed milk powder substitute
EP0947464A1 (en) * 1998-04-01 1999-10-06 Single Buoy Moorings Inc. Fluid transfer boom with coaxial fluid ducts
US20030005468A1 (en) * 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
ATE427653T1 (de) * 1998-11-19 2009-04-15 Pharming Intellectual Pty Bv Stabilisierung der milch transgener tieren
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1194033B1 (en) * 1999-05-13 2007-12-19 GTC Biotherapeutics, Inc. Transgenically produced antithrombin iii and mutants thereof
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040226052A1 (en) * 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
AU2002252310A1 (en) * 2001-03-12 2002-09-24 Stephen P Butler Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
AU2002307554A1 (en) * 2001-04-23 2002-11-05 Abgenix, Inc. Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
JP2005519580A (ja) * 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
NZ529767A (en) * 2001-06-13 2005-10-28 Taurus Hsa Llc Purification of human serum albumin
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
KR100473703B1 (ko) * 2002-08-23 2005-03-10 한미약품 주식회사 형질전환 동물의 젖으로부터 재조합 펩타이드 또는단백질의 정제 방법
TWI268933B (en) * 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
WO2005112968A2 (en) * 2004-04-30 2005-12-01 Gtc Biotherapeutics, Inc. Method of using recombinant human antithrombin for neurocognitive disorders
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP1802341A1 (en) * 2004-07-16 2007-07-04 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US7910100B2 (en) * 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
EP1868647A4 (en) 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
MX2007013217A (es) * 2005-04-25 2008-03-11 Pfizer Anticuerpos contra miostatina.
AP2552A (en) 2005-04-26 2013-01-08 Pfizer P-cadherin antibodies
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
PL2960253T3 (pl) 2005-09-07 2018-11-30 Amgen Fremont Inc. Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1
EP1954311A4 (en) 2005-12-07 2009-12-23 Medarex Inc CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY
JP5376574B2 (ja) 2005-12-15 2013-12-25 ゲンマブ エー／エス 自己免疫疾患の治療のためのエフェクター機能欠乏抗体の使用
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
AU2007281774A1 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to ErbB 2
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
CN101511387A (zh) * 2006-09-08 2009-08-19 惠氏公司 使用亲和色谱法纯化蛋白质的精氨酸洗涤液
SI2081595T1 (sl) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
US8020576B2 (en) * 2006-10-26 2011-09-20 Delaware Capital Formation, Inc. Emergency shutoff valve for use in a fuel dispensing system
JP5570218B2 (ja) 2006-11-03 2014-08-13 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆｇｆｒ４抗体
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
EP2918605A1 (en) 2007-11-12 2015-09-16 U3 Pharma GmbH Axl antibodies
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
EP2944649A1 (en) 2008-01-10 2015-11-18 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
RU2498998C2 (ru) 2008-05-30 2013-11-20 ИксБиотеч, Инк. АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2270053A1 (en) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
KR101834890B1 (ko) 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
WO2011084145A2 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
EP2384766A1 (en) 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
JP6189751B2 (ja) 2010-12-30 2017-08-30 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 病原体不活性化剤としてのグリコール
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP6178311B2 (ja) * 2011-07-07 2017-08-09 エルエフビー ユーエスエー インコーポレイテッドＬｆｂ Ｕｓａ， Ｉｎｃ． タンパク質を安定化する製剤
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
PL2581387T3 (pl) 2011-10-11 2016-04-29 Univ Aix Marseille Przeciwciało monoklonalne anty-Tat HIV-1
CN104271599A (zh) 2011-11-08 2015-01-07 辉瑞公司 使用抗m-csf抗体治疗炎性疾病的方法
EP3093293A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
MX2015010427A (es) 2013-02-13 2016-03-17 Lab Francais Du Fractionnement Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
MX2016000063A (es) 2013-07-05 2016-03-01 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
EP3338793A1 (en) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Novel sez6 modulators and methods of use
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
CA2959356C (en) 2014-08-27 2024-02-20 Memorial Sloan Kettering Cancer Center Novel antibodies that bind to b7h3
IL250902B (en) 2014-09-16 2022-08-01 Symphogen As Anti-met antibodies and preparations
CN108368169A (zh) 2015-03-18 2018-08-03 约翰霍普金斯大学 靶向钾通道kcnk9的新的单克隆抗体抑制剂
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
EP3334761B1 (en) 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
JP2019507582A (ja) 2015-12-04 2019-03-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法用のｓｌｃ４５ａ２ペプチド
TN2018000419A1 (en) 2016-07-12 2020-06-15 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof.
EP3491136A1 (en) 2016-07-28 2019-06-05 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Anti- immunoglobulin g aptamers and uses thereof
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
WO2018109213A1 (en) 2016-12-16 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Aptamers directed against a kappa light chain-containing protein and uses thereof
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018119380A2 (en) 2016-12-23 2018-06-28 Bristol-Myers Squibb Company Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
AR112336A1 (es) 2017-07-14 2019-10-16 Pfizer ANTICUERPOS CONTRA MAdCAM
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
IL307925A (en) 2018-05-07 2023-12-01 Genmab As Combination of an antibody against 1-PD and conjugation of a drug with an antibody against TF for use in the treatment of cancer
TW202010755A (zh) 2018-05-07 2020-03-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
TW202034958A (zh) 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
EP4054647A1 (en) 2019-11-04 2022-09-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
WO2021090272A1 (en) 2019-11-07 2021-05-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2021110561A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
CA3172880A1 (en) 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
WO2022002940A1 (en) 2020-06-29 2022-01-06 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4175982A1 (en) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
JP2023549581A (ja) 2020-11-17 2023-11-27 シージェン インコーポレイテッド ツカチニブ及び抗ｐｄ－１／抗ｐｄ－ｌ１抗体の組み合わせによりがんを治療する方法
WO2022258720A1 (en) 2021-06-09 2022-12-15 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024036265A2 (en) 2022-08-12 2024-02-15 Takeda Vaccines, Inc. Novel anti-denv3 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5165945A (en) * 1987-07-23 1992-11-24 Schreiber Foods, Inc. Cheese and process and system for making it
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
JPH04365487A (ja) * 1990-04-11 1992-12-17 Consortium Elektrochem Ind Gmbh 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳
US5175013A (en) * 1990-12-31 1992-12-29 The Pillsbury Company Frozen dessert compositions and products
FR2677652B1 (fr) * 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
US5178894A (en) * 1991-09-26 1993-01-12 Silvia P. Rudel High non-fat milk content bread products having improved keeping qualities

Also Published As

Publication number Publication date
WO1994019935A1 (en) 1994-09-15
EP0804070B1 (en) 2000-05-24
PT804070E (pt) 2000-11-30
JP3801196B2 (ja) 2006-07-26
DK0804070T3 (da) 2000-08-07
ATE193301T1 (de) 2000-06-15
AU693436B2 (en) 1998-07-02
JPH08510721A (ja) 1996-11-12
GR3033500T3 (en) 2000-09-29
DE69424687D1 (de) 2000-06-29
EP0804070A1 (en) 1997-11-05
US5756687A (en) 1998-05-26
DE69424687T2 (de) 2000-09-07
AU6268394A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
ES2146648T3 (es) Procedimiento de aislamiento de proteinas de la leche.
FI883708A (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
FI963197A0 (fi) Laktoferriinin eristäminen maidosta
DE69207228T2 (de) Isolierverfahren von Proteinen durch Ultrafiltration
NO20001052D0 (no) 1C, 15N, 2H merkede proteiner for NMR-strukturbestemmelser og deres fremstilling
KR950700779A (ko) 단백질의 정제방법(Protein purification)
DK162233C (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
CY1105206T1 (el) Διαδικασια για την εκχυλιση και χρησιμοποιηση υγρου επωασης απο σολομο του ατλαντικου
DE3865963D1 (de) Elektrophoretisches gel hoher aufloesung sowie methode zur abscheidung von serumproteinen.
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
DE3574479D1 (de) Citronensaeureester als treibmittel zur kunststoffverarbeitung.
DE3865998D1 (de) Verfahren und system zur gewinnung und ausscheidung von effekten gleichzeitig auftretender quellen eines elektromagnetischen feldes und ihre anwendung bei der vorhersage von erdbeben.
GB2263279A (en) Separation of proteins and dyes
DK260186D0 (da) Fremgangsmaade til fjernelse af det n-terminale metionin fra metionylproteiner
GR3025929T3 (en) Ein isolation and purification of lung surfactant prot
IL127278A0 (en) Methods for determining the presence of brain protein s-100
HU896448D0 (en) Process for the preparation of anticoagulant peptides
CA2157118A1 (en) Isolation of components of interest from milk
AU5749198A (en) Crystallisation of proteins
GB2110221A (en) Process for isolation of proteins from plant leaves
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner
Estborn et al. Localisation of acid phosphatase by starch-gel electrophoresis of fractionally collected human semen
DK412389D0 (da) Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK1104489T3 (da) Fremgangsmåde til adskillelse og karakterisering af de funktioner, der potentielt er til stede i en biologisk pröve, som indeholder nukleinsyrer
Beveridge Comparison of the Protein Content in Selected Tissues at Different Feeding Stages in the American Dog Tick Dermacentor variabilis (Say)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 804070

Country of ref document: ES